Wragge Lawrence Graham & Co
- Corporate (31)
- Funds (19)
- Banking / Finance (17)
- Real Estate (17)
- Information Technology (12)
- Financial services (9)
- Intellectual Property (9)
- Pharma/Biotech (9)
- PPP/PFI/Commercial projects (9)
- Construction (8)
- Employment (8)
- Tax (8)
- Regulatory and compliance (7)
- Energy (6)
- Pensions (6)
- Public Sector/Local Authority (6)
- Competition/EU (5)
- Litigation / Dispute Resolution (5)
- Planning (5)
- Private Equity (5)
- Healthcare (4)
- Telecoms (4)
- Business Tax (3)
- Environment (3)
- Insurance/reinsurance (3)
- Insolvency & restructuring (2)
- Media/Entertainment/Sport (2)
- Personal tax / Trusts (2)
- Transport (Including aviation and shipping) (2)
- Travel and Tourism (2)
- Commodities (1)
- Consumer/Retail (1)
- In-House (1)
- Licensing/Gaming/Betting (1)
- Private Client (1)
Sort By: Newest first | Oldest first
Wragge Lawrence Graham & Co has advised Stan West and the senior management of GSF Car Parts, the UK’s largest independent distributor of car parts, on its sale to HgCapital’s The Parts Alliance.
Wragge Lawrence Graham & Co (WLG) has advised longstanding client Santander Growth Capital team in relation to the financing package it has made available to Aspinal of London.
The investment funds team at Wragge Lawrence Graham & Co has acted on half of the IPOs and significant secondary issues for listed investment companies in the first half of 2015.
Wragge Lawrence Graham & Co’s life sciences experts have advised AstraZeneca on its definitive agreement with Genzyme to divest Caprelsa (vandetanib), a rare disease medicine.
Wragge Lawrence Graham & Co has provided Empiric Student Property plc (Empiric) with advice on its first corporate acquisition, at a value of £41.6m.
Wragge Lawrence Graham & Co’s intellectual property experts in Munich have worked with Ashurst LLP to advise Novacap Group on its acquisition of pharmaceutical company CU Chemie Uetikon.
Wragge Lawrence Graham & Co has advised AstraZeneca on a co-development and commercialisation agreement with Innate Pharma SA, a biopharmaceutical company developing therapeutic antibodies for the treatment of cancer.
Wragge Lawrence Graham & Co’s investment funds team has advised AEW UK REIT Plc on a fundraising worth £100m.
Wragge Lawrence Graham & Co’s tech team has helped new client Breezie to secure investment from the Ziegler LinkAge Longevity Fund.
Wragge Lawrence Graham & Co’s banking and finance team have advised the North West Evergreen Fund on its £15m investment to Allied London to part-fund the development of No.1 Spinningfields in Manchester.
A team from the banking and finance department has advised Harworth Estates Property Group on the refinancing of its group banking facilities.
Wragge Lawrence Graham & Co’s investment funds team has advised Empiric Student Property plc on an £85m fund raising, exceeding its target of approximately £75m.
Wragges has advised long-standing client on a three-year drug discovery collaboration agreement with Orca.
Wragge Lawrence Graham & Co has advised longstanding client Société Générale Capital Partners on the leveraged buyout of specialty chemicals distributor Safic-Alcan from Parquest Capital.
Wragge Lawrence Graham & Co has advised GlaxoSmithKline (GSK) on the sale of its shareholding interests in biopharmaceutical company Convergence Pharmaceuticals to Biogen Idec.
Wragge Lawrence Graham & Co secures a High Court win over design rights for worldwide denim specialist G-Star Raw.
Wragge Lawrence Graham & Co has advised high-street retailer and long-standing client Argos on its arrangement with Sainsbury’s to launch a series of new Argos digital stores within a number of its UK supermarkets.
Wragge Lawrence Graham & Co has advised Birmingham City Council on the sale of the NEC Group to LDC.
The energy & infrastructure dinance team at Wragge Lawrence Graham & Co has advised longstanding client Primrose Solar on two inflation-linked financings.
Wragge Lawrence Graham & Co has advised Riviera Travel on a significant investment made into the company by private equity firm, Phoenix Equity Partners.